

Anti-CEACAM5-SN38(Dar6)[Labetuzumab govitecan]


Product Information

Product Name	Anti-CEACAM5-SN38(Dar6)[Labetuzumab govitecan]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87845AB-100 / 100 µg GM-87845AB-1mg / 1 mg

Antibody Information


Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	5.0-6.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	CEACAM5
Clone	Labetuzumab govitecan
Alternative Names	CD66e, CEA
Source/Isotype	Monoclonal Human IgG1, kappa
Application	Positive control of Cytotoxicity Assay
Description	Labetuzumab govitecan is an antibody-drug conjugate (ADC) targeting CEACAM5. Its mechanism of action involves the antibody (labetuzumab) specifically binding to CEACAM5, which is highly expressed on the surface of cancer cells, and being internalized into the cell via endocytosis. In the intracellular environment of tumor cells, the linker attached to the antibody is enzymatically cleaved to release SN-38 (a topoisomerase I inhibitor), which blocks DNA replication and transcription, ultimately leading to cancer cell death. Additionally, the released SN-38 can diffuse to neighboring tumor cells, generating a bystander effect that further enhances the overall antitumor efficacy. This targeted drug delivery mechanism not only significantly improves therapeutic outcomes but also effectively reduces toxicity to normal tissues.
Formulation	Phosphate-buffered solution, pH 7.2-7.4. Version:3.1

SDS-PAGE





On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

RP-HPLC



The drug-to-antibody ratio (DAR) of this product is 5.83.